The effect of drug dose and drug exposure time on the binding, internalization, and cytotoxicity of radiolabeled somatostatin analogs

Journal of Surgical Research

Volumn 119, Issue 1, 2004, Pages 1-13

  Anthony, Catherine T ^a   Hughey, Susan ^a   Lyons, John ^a   Weiss, Sean ^a   Hornick, Conrad A ^a   Drouant, George J ^a   Fuselier, Joseph A ^b   Coy, David H ^b   Murphy, William A ^b   Woltering, Eugene A ^a,c,d  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TULANE UNIVERSITY   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

cytotoxicity; internalization; irradiation; membrane binding; somatostatin

Indexed keywords

INDIUM 111; PENTETREOTIDE; RADIOLIGAND; SOMATOSTATIN DERIVATIVE;

ARTICLE; BINDING AFFINITY; CELL ACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG BINDING; DRUG EXPOSURE; ENERGY YIELD; EXPERIMENTAL TEST; GAMMA RADIATION; HUMAN; HUMAN CELL; INCUBATION TIME; INTERNALIZATION; ISOTOPE LABELING; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE;

BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDIUM RADIOISOTOPES; OSMOLAR CONCENTRATION; RADIOLIGAND ASSAY; SOMATOSTATIN; TIME FACTORS;

EID: 2342509665     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jss.2003.06.002     Document Type: Article

References (24)

1. Patel Y.C. Somatostatin and its receptor family. Front. Neuroendocrinol. 20:1999;157
2. Schonbrunn A., Gu Y.Z., Dournard P., Beaudet A., Tannenbaum G.S., Brown P.J. Somatostatin receptor subtypes Specific expression and signaling properties. Metabolism. 45:(8 Suppl 1):1996;8
3. Meyerhof W. The elucidation of somatostatin receptor functions A current view. Rev. Physiol. Biochem. Pharmacol. 133:1998;55
4. Woltering E.A., O'Dorisio M.S., O'Dorisio T.M. The role of radiolabeled somatostatin analogs in the management of cancer patients. DeVita V. PPO Updates. Vol. 9:1995;1-16 Lippincott Healthcare Publications, Philadelphia, PA
5. Woltering E.A., O'Dorisio M.S., Murphy W.A., Chen F., Drouant G.J., Espenan G.D., Fisher D.R., Sharma C., Diaco D.S., Maloney T.M., Fuselier J.A., Nelson J.A., O'Dorisio T.M., Coy D.H. Synthesis and characterization of multiply-tyrosinated, multiply-iodinated somatostatin analogs. J. Pept. Res. 53:(2):1999;201
6. Schonbrunn A., Gu Y.Z., Brown P.J., Loose-Mitchell D. Function and regulation of somatostatin receptor subtypes. Ciba Found. Symp. 190:1995;204
7. Hipkin R.W., Friedman J., Clark R.B., Eppler C.M., Schonbrunn A. Agonist-induced desensitization, internalization, and phosphorylation of the sst 2A somatostatin receptor. J. Biol. Chem. 272:(21):1997;13869
8. Sarret P., Nouel D., Dal Farra C., Vincent J.P., Beaudet A., Mazella J. Receptor-mediated internalization of the expression of growth hormone by somatostatin in the pituitary cell line AtT-20. J. Biol. Chem. 274:(27):1999;19294
9. Hofland L.J., van Koetsveld P.M., Wouters N., Waaijers M., Reubi J.C., Lamberts S.W.J. Dissociation of the antiproliferative and antihormonal effects of the somatostatin analog octreotide on 7315b pituitary tumor cells. Endocrinology. 131:(2):1992;571
10. Hipkin R.W., Wang Y., Schonbrunn A. Protein kinase C activation stimulates the phosphorylation and internalization of the sst 2A somatostatin receptor. J. Biol. Chem. 275:(8):2000;5591
11. Patel P.C., Barrie R., Hill N., Landeck S., Kurozawa D., Woltering E.A. Postreceptor signal transduction mechanisms involved in octreotide-induced inhibition of angiogenesis. Surgery. 116:(6):1994;1148
12. Hornick C.A., Anthony C.T., Hughey S., Gebhardt B.M., Espenan G.D., Woltering E.A. Progressive nuclear translocation of somatostatin analogs. J. Nucl. Med. 41:(7):2000;1256
13. Meyers M.O., Anthony C.T., Coy D.H., Murphy W.A., Drouant G.J., Fuselier J., Espenan G.D., Maloney T.J., Woltering E.A. Multiply radioiodinated somatostatin analogs induce receptor-specific cytotoxicity. J. Surg. Res. 76:(2):1998;154
14. 111In-pentetreotide Initial observations and future directions. Cancer J. Sci. Am. 4:(2):1998;94
15. Espenan G.D., Nelson J.A., Fisher D.R., Diaco D.S., McCarthy K.E., Anthony L.B., Maloney T.J., Woltering E.A. Experiences with high-dose radiopeptide therapy The health physics perspective. Health Phys. 76:(3):1999;225
16. 111In-DTPA-JIC 2DL. J. Surg. Res. 97:(2):2001;131
17. O'Dorisio M.S., Chen F., O'Dorisio T.M., Wray D., Qualman S.J. Characterization of somatostatin receptors on human neuroblastoma tumors. Cell Growth Differ. 5:(1):1994;1
18. Sussman K.E., Mehler P.S., Leitner J.W., Draznin B. Role of the secretion vesicle in the transport of receptors Modulation of somatostatin binding to pancreatic islets. Endocrinology. 111:(1):1982;316
19. 3 octreotide by mouse and human pituitary tumor cells Increase by unlabeled octreotide. Endocrinology. 136:(9):1995;3698
20. Koenig J.A., Edwardson J.M., Humphrey P.P.A. Somatostatin receptors in Neuro2A neuroblastoma cells Ligand internalization. Br. J. Pharmacol. 120:(1):1997;52
21. 111In-DTPA-D-Phe1-octreotide in patients with neuroendocrine tumors. J. Nucl. Med. 41:(9):2000;1514
22. 111In-labeled oligodeoxyribonucleotides. J. Nucl. Med. 41:(6):2000;1093
23. Gulec S.A., Gaffga C.M., Anthony C.T., Su L.J., O'Leary J.P., Woltering E.A. Antiangiogenic therapy with somatostatin receptor-mediated in situ radiation. Am. Surg. 67:(11):2001;1068
24. Watson J.C., Balster D.A., Gebhardt B.M., O'Dorisio T.M., O'Dorisio M.S., Espenan G.D., Drouant G.J., Woltering E.A. Growing vascular endothelial cells express somatostatin subtype 2 receptors. Br. J. Cancer. 85:(2):2001;266